Cannabinoid antagonist in nanostructured lipid carriers (NLCs): Design, characterization and in vivo study

Materials Science and Engineering C

Volumn 48, Issue , 2015, Pages 328-336

  Esposito, Elisabetta ^a   Ravani, Laura ^a   Drechsler, Markus ^b   Mariani, Paolo ^c   Contado, Catia ^a   Ruokolainen, Janne ^d   Ratano, Patrizia ^e   Campolongo, Patrizia ^e   Trezza, Viviana ^f   Nastruzzi, Claudio ^a   Cortesi, Rita ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF BAYREUTH   (Germany)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^d AALTO UNIVERSITY   (Finland)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f ROMA TRE UNIVERSITY   (Italy)

Author keywords

Cryogenic transmission electron microscopy; Drug delivery; Nanostructured lipid carriers; Photon correlation spectroscopy; Rimonabant

Indexed keywords

CRYOGENICS; DRUG DELIVERY; EMULSIONS; LIQUID CHROMATOGRAPHY; PHOTONS; QUANTUM OPTICS; RATS; TRANSMISSION ELECTRON MICROSCOPY;

CANNABINOID ANTAGONIST; CRYOGENIC TRANSMISSION ELECTRON MICROSCOPY; CRYOGENIC TRANSMISSION ELECTRON MICROSCOPY (CRYO-TEM); DIFFERENT PROTOCOLS; NANOSTRUCTURED LIPID CARRIERS; OPTIMAL STRATEGIES; RIMONABANT; SEDIMENTATION FIELD FLOW FRACTIONATION;

PHOTON CORRELATION SPECTROSCOPY;

CANNABINOID RECEPTOR ANTAGONIST; LIPID; NANOCAPSULE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; RIMONABANT;

ANIMAL; CHEMISTRY; MALE; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; CANNABINOID RECEPTOR ANTAGONISTS; LIPIDS; MALE; NANOCAPSULES; PIPERIDINES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84918579208     PISSN: 09284931     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.msec.2014.12.012     Document Type: Article

References (57)

1. R.G. Pertwee Inverse agonism and neutral antagonism at cannabinoid CB1 receptors Life Sci. 76 2005 1307 1324
2. D.R. Janero, and A. Makriyannis Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis Expert Opin. Emerg. Drugs 14 2009 43 65
3. P. Pacher, S. Batkai, and G. Kunos The endocannabinoid system as an emerging target of pharmacotherapy Pharmacol. Rev. 58 2006 389 462
4. K. Mackie Cannabinoid receptors as therapeutic targets Annu. Rev. Pharmacol. Toxicol. 46 2006 101 122
5. V. Trezza, and P. Campolongo The endocannabinoid system as a possible target to treat both the cognitive and emotional features of post-traumatic stress disorder (PTSD) Front. Behav. Neurosci. 7 2013 1 5
6. M. Morena, and P. Campolongo The endocannabinoid system: an emotional buffer in the modulation of memory function Neurobiol. Learn. Mem. 2013 10.1016/j.nlm.2013.12.010 (pii: S1074-7427(13)00266-9, [Epub ahead of print])
7. P. Campolongo, M. Morena, S. Scaccianoce, V. Trezza, F. Chiarotti, G. Schelling, V. Cuomo, and B. Roozendaal Novelty-induced emotional arousal modulates cannabinoid effects on recognition memory and adrenocortical activity Neuropsychopharmacology 38 2013 1276 1286
8. V. Trezza, R. Damsteegt, A. Manduca, S. Petrosino, L.W. Van Kerkhof, R.J. Pasterkamp, Y. Zhou, P. Campolongo, V. Cuomo, V. Di Marzo, and L.J. Vanderschuren Endocannabinoids in amygdala and nucleus accumbens mediate social play reward in adolescent rats J. Neurosci. 32 2012 14899 14908
9. P. Pacher, and G. Kunos Modulating the endocannabinoid system in human health and disease - successes and failures FEBS J. 280 2013 1918 1943
10. R.G. Pertwee Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities Philos. Trans. R. Soc. Lond. B Biol. Sci. 367 2012 3353 3363
11. D.H. Pérez de la Ossa, A. Ligresti, M.E. Gil-Alegre, M.R. Aberturas, J. Molpeceres, V. Di Marzo, and A. Torres Suárez Poly-ε-caprolactone microspheres as a drug delivery system for cannabinoid administration: development, characterization and in vitro evaluation of their antitumoral efficacy J. Control. Release 161 2012 927 932
12. L. Battaglia, and M. Gallarate Lipid nanoparticles: state of the art, new preparation methods and challenges in drug delivery Expert Opin. Drug Deliv. 9 2012 497 508
13. A.M. Nyström, and B. Fadeel Safety assessment of nanomaterials: implications for nanomedicine J. Control. Release 16 2012 403 408
14. M. Uner, and G. Yener Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives Int. J. Nanomedicine 2 2007 289 300
15. M.D. Joshi, and R.H. Müller Lipid nanoparticles for parenteral delivery of actives Eur. J. Pharm. Biopharm. 71 2009 161 172
16. A. Saupe, S.A. Wissing, A. Lenk, C. Schmidt, and R.H. Müller Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) - structural investigations on two different carrier systems Biomed. Mater. Eng. 15 2005 393 402
17. G. Yoon, J.W. Park, and I.-S. Yoon Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs): recent advances in drug delivery J. Pharm. Investig. 43 2013 353 362
18. S.S. Shidhaye, R. Vaidya, S. Sutar, A. Patwardhan, and V.J. Kadam Solid lipid nanoparticles and nanostructured lipid carriers - innovative generations of solid lipid carriers Curr. Drug Deliv. 5 2008 324 331
19. A. Puri, K. Loomis, B. Smith, J.H. Lee, A. Yavlovich, E. Heldman, and R. Blumenthal Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic Crit. Rev. Ther. Drug Carrier Syst. 26 2009 523 580
20. R. Christensen, P.K. Kristensen, E.M. Bartels, H. Bliddal, and A. Astrup Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials Lancet 370 2007 1706 1713
21. K. Johansson, K. Neovius, S.M. DeSantis, S. Rössner, and M. Neovius Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis Obes. Rev. 10 2009 564 575
22. K. Jores, W. Mehnert, M. Drechsler, H. Bunjes, C. Johann, and K. Maeder Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy J. Control. Release 95 2004 217 227
23. E. Esposito, M. Fantin, M. Marti, M. Drechsler, L. Paccamiccio, P. Mariani, E. Sivieri, F. Lain, E. Menegatti, M. Morari, and R. Cortesi Solid lipid nanoparticles as delivery systems for bromocriptine Pharm. Res. 25 2008 1521 1530
24. V. Luzzati, H. Delacroix, T. Gulik-Krzywicki, P. Mariani, and R. Vargas The cubic phases of lipids Curr. Top. Membr. 44 1997 3 24
25. R. Pecora Dynamic light scattering measurement of nanometer particles in liquids J. Nanoparticle Res. 2 2000 123 131
26. C. Contado, A. Dalpiaz, E. Leo, M. Zborowski, and P.S. Williams Complementary use of flow and sedimentation field-flow fractionation techniques for size characterizing biodegradable poly(lactic acid) nanospheres J. Chromatogr. A 1157 2007 321 335
27. C. Contado, G. Blo, F. Fagioli, F. Dondi, and R. Beckett Characterisation of River Po particles by sedimentation field-flow fractionation coupled to GFAAS and ICP-MS Colloids Surf. A 120 1997 47 59
28. A.P. Nayak, W. Tiyaboonchai, S. Patankar, B. Madhusudhan, and E.B. Souto Curcuminoids loaded lipid nanoparticles: novel approach towards malaria treatment Colloids Surf. B 81 2010 263 273
29. C. Puglia, V. Cardile, A.M. Panico, L. Crascì, A. Offerta, S. Caggia, M. Drechsler, P. Mariani, R. Cortesi, and E. Esposito Evaluation of monooleine aqueous dispersions as tools for topical administration of curcumin: characterization, in vitro and ex-vivo studies J. Pharm. Sci. 102 2013 2349 2361
30. E. Esposito, E. Menegatti, and R. Cortesi Hyaluronan based microspheres as tools for drug delivery: a comparative study Int. J. Pharm. 288 2005 35 49
31. B. Bosier, S. Sarre, I. Smolders, Y. Michotte, E. Hermans, and D.M. Lambert Revisiting the complex influences of cannabinoids on motor functions unravels pharmacodinamic differences between cannabinoid agonists Neuropharmacology 59 2010 503 510
32. M. Bortolato, P. Campolongo, R.A. Mangieri, M.L. Scattoni, R. Frau, V. Trezza, G. La Rana, R. Russo, A. Calignano, G.L. Gessa, V. Cuomo, and D. Pionelli Anxiolytic-like properties of the anandamide transport inhibitor AM404 Neuropsychopharmacology 31 2006 2652 2659
33. P. Campolongo, V. Trezza, P. Ratano, M. Palmery, and V. Cuomo Developmental consequences of perinatal cannabis exposure: behavioral and neuroendocrine effects in adult rodents Psychopharmacology (Berl) 214 2011 5 15
34. U. Bhaumik, A. Ghosh, B. Chatterjee, P. Sengupta, S. Darbar, B. Roy, U. Nandi, and T.K. Pal Development and validation of a high-performance liquid chromatographic method for bioanalytical application with rimonabant J. Pharm. Biomed. Anal. 49 2009 1009 1013
35. J. Kreuter, V.E. Petrov, D.A. Kharkevich, and R.N. Alyautdin Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood-brain barrier using surfactant-coated nanoparticles J. Control. Release 49 1997 81 87
36. P. Ramge, R.E. Unger, B. Oltrogge, D. Zenker, D. Begley, J. Kreuter, and H. von Briesen Polysorbate-80 coating enhances uptake of polybutylcyanoacrylate (PBCA) nanoparticles by human and bovine primary brain capillary endothelial cells Eur. J. Neurosci. 12 2000 1931 1940
37. A.E. Gulyaev, S.E. Gelperina, I.N. Skidan, A.S. Antropov, G.Y. Kivman, and J. Kreuter Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles Pharm. Res. 16 1999 1564 1569
38. T.M. Göppert, and R.H. Müller Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: comparison of plasma protein adsorption patterns J. Drug Target. 13 2005 179 187
39. X.H. Tian, X.N. Lin, F. Wei, Z.C. Huang, P. Wang, L. Ren, and Y. Diao Enhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticles Int. J. Nanomedicine 6 2011 445 452
40. E. Esposito, P. Mariani, L. Ravani, C. Contado, M. Volta, S. Bido, M. Drechsler, S. Mazzoni, E. Menegatti, M. Morari, and R. Cortesi Nanoparticulate lipid dispersions for bromocriptine delivery: characterization and in vivo study Eur. J. Pharm. Biopharm. 80 2012 306 314
41. M. Siewert, J. Dressman, C.K. Brown, and V.P. Shah FIP/AAPS guidelines to dissolution/in vitro release testing of novel/special dosage forms AAPS PharmSciTech 4 2003 E7
42. E. Toitou, and B. Fabin Altered skin permeation of highly lipophilic molecule: tetrahydrocannabinol Int. J. Pharm. 43 1988 17 22
43. N.A. Peppas Analysis of Fickian and non-Fickian drug release from polymers Pharm. Acta Helv. 60 1985 110 111
44. J. Lee, and I.W. Kellaway The controlled release of drugs from cubic phases of glyceryl monooleate M.L. Lynch, P.T. Spicer, Bicontinuous Liquid Crystals 2005 CRC Press, Taylor & Francis Group Boca Raton (FL) 457 469
45. L. Illum Nasal drug delivery - possibilities, problems and solutions J. Control. Release 87 2003 187 198
46. C.L. Graff, and G.M. Pollack Nasal drug administration: potential for targeted central nervous system delivery J. Pharm. Sci. 94 2005 1187 1195
47. H.R. Costantino, L. Illum, G. Brandt, P.H. Johnson, and S.C. Quay Intranasal delivery: physicochemical and therapeutic aspects Int. J. Pharm. 337 2007 1 24
48. S.V. Dhuria, L.R. Hanson, and W.H. Frey Intranasal delivery to the central nervous system: mechanisms and experimental considerations J. Pharm. Sci. 99 2010 1654 1673
49. A. Pires, A. Fortuna, G. Alves, and A. Falcão Intranasal drug delivery: how, why and what for? J. Pharm. Pharm. Sci. 12 2009 288 311
50. L. Illum Transport of drugs from the nasal cavity to the central nervous system Eur. J. Pharm. Sci. 11 2000 1 18
51. Q.-Z. Zhang, L.-S. Zha, Y. Zhang, W.-M. Jiang, W. Lu, Z.-Q. Shi, X.-G. Jiang, and S.-K. Fu The brain targeting efficiency following nasally applied MPEG-PLA nanoparticles in rats J. Drug Target. 14 2006 281 290
52. H. Yang Nanoparticle-mediated brain-specific drug delivery, imaging, and diagnosis Pharm. Res. 27 2010 1759 1771
53. 14C]poly(butyl cyanoacrylate) nanoparticles after i.v. administration in rats J. Drug Target. 13 2005 535 542
54. Y. Ruan, L. Yao, B. Zhang, S. Zhang, and J. Guo Antinociceptive properties of nasal delivery of neurotoxin-loaded nanoparticles coated with polysorbate-80 Peptides 32 2011 1526 1529
55. M.L. Amin P-glycoprotein inhibition for optimal drug delivery Drug Target Insights 7 2013 27 34
56. C.L. Graff, and G.M. Pollack Functional evidence for P-glycoprotein at the nose-brain barrier Pharm. Res. 22 2005 86 93
57. U. Westin, E. Piras, B. Jansson, U. Bergström, M. Dahlin, E. Brittebo, and E. Björk Transfer of morphine along the olfactory pathway to the central nervous system after nasal administration to rodents Eur. J. Pharm. Sci. 24 2005 565 573